IRIS
DE SANCTIS, Rita
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.445
AS - Asia 2.597
SA - Sud America 897
EU - Europa 818
AF - Africa 137
Continente sconosciuto - Info sul continente non disponibili 15
OC - Oceania 9
Totale 7.918
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.336
SG - Singapore 1.470
BR - Brasile 754
CN - Cina 448
VN - Vietnam 368
IT - Italia 159
FI - Finlandia 139
IE - Irlanda 113
DE - Germania 84
FR - Francia 69
NG - Nigeria 69
CA - Canada 65
AR - Argentina 60
HK - Hong Kong 57
GB - Regno Unito 54
IN - India 49
TR - Turchia 43
SE - Svezia 34
NL - Olanda 33
MX - Messico 32
BD - Bangladesh 28
RU - Federazione Russa 28
EC - Ecuador 26
IQ - Iraq 24
ZA - Sudafrica 21
ES - Italia 20
ID - Indonesia 18
IL - Israele 16
MA - Marocco 16
BE - Belgio 15
CL - Cile 14
CO - Colombia 13
UA - Ucraina 12
JP - Giappone 11
EU - Europa 10
PY - Paraguay 10
EG - Egitto 9
VE - Venezuela 9
PL - Polonia 8
AU - Australia 7
CZ - Repubblica Ceca 7
PK - Pakistan 7
RO - Romania 7
SA - Arabia Saudita 7
IR - Iran 6
NP - Nepal 6
KE - Kenya 5
PE - Perù 5
UZ - Uzbekistan 5
AZ - Azerbaigian 4
DZ - Algeria 4
GR - Grecia 4
JM - Giamaica 4
JO - Giordania 4
LT - Lituania 4
PH - Filippine 4
SN - Senegal 4
A2 - ???statistics.table.value.countryCode.A2??? 3
AT - Austria 3
BO - Bolivia 3
BW - Botswana 3
BY - Bielorussia 3
CR - Costa Rica 3
ET - Etiopia 3
HR - Croazia 3
KZ - Kazakistan 3
MD - Moldavia 3
NO - Norvegia 3
OM - Oman 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AM - Armenia 2
HN - Honduras 2
MK - Macedonia 2
MY - Malesia 2
NZ - Nuova Zelanda 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
XK - ???statistics.table.value.countryCode.XK??? 2
AF - Afghanistan, Repubblica islamica di 1
BH - Bahrain 1
CI - Costa d'Avorio 1
DK - Danimarca 1
EE - Estonia 1
GA - Gabon 1
GE - Georgia 1
IM - Isola di Man 1
JE - Jersey 1
KG - Kirghizistan 1
KR - Corea 1
KW - Kuwait 1
MN - Mongolia 1
MR - Mauritania 1
NI - Nicaragua 1
PA - Panama 1
PT - Portogallo 1
QA - Qatar 1
TH - Thailandia 1
TT - Trinidad e Tobago 1
Totale 7.917
Salva come PNG Salva come JPEG
Città #
Singapore 617
Wilmington 467
Ashburn 289
Chandler 232
The Dalles 222
San Jose 183
San Mateo 172
Shanghai 172
Ann Arbor 166
Dallas 165
Helsinki 139
New York 119
Ho Chi Minh City 115
Dublin 113
Beijing 109
Leawood 101
Hanoi 95
Boardman 90
Lawrence 85
Princeton 85
São Paulo 71
Benin City 67
Fairfield 56
Hong Kong 54
Paris 53
Woodbridge 44
Toronto 43
Los Angeles 39
Rio de Janeiro 37
Kocaeli 31
Santa Clara 31
Amsterdam 27
London 26
Milan 20
Seattle 17
Assago 16
Phoenix 16
Brussels 15
Orem 15
Curitiba 13
Da Nang 13
Hải Dương 13
Brasília 12
Guayaquil 12
Monmouth Junction 12
Montreal 12
Chennai 11
Mexico City 11
Buenos Aires 10
Fortaleza 10
Haiphong 10
Johannesburg 10
Munich 10
Recife 10
Tokyo 10
Biên Hòa 9
Brooklyn 9
Naples 9
Porto Alegre 9
Atlanta 8
Baghdad 8
Buffalo 8
Chicago 7
Council Bluffs 7
Falkenstein 7
Natal 7
Pune 7
Quito 7
Belo Horizonte 6
Brno 6
Casablanca 6
Dhaka 6
Erbil 6
Hillsboro 6
New Delhi 6
Norwalk 6
Osasco 6
Salvador 6
San Diego 6
San Francisco 6
Santiago 6
Warsaw 6
Abbiategrasso 5
Asunción 5
Bắc Ninh 5
Cachoeirinha 5
Cairo 5
Campinas 5
Franca 5
Frankfurt am Main 5
Manaus 5
Nairobi 5
Ninh Bình 5
Ribeirão Preto 5
Sorocaba 5
São Bernardo do Campo 5
Tashkent 5
Thái Bình 5
Uberlândia 5
Amman 4
Totale 4.868
Salva come PNG Salva come JPEG
Nome #
Biological characteristics and long-term outcomes in node-negative breast cancer 119
Palonosetron plus three-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy 118
Treatment of malignant pleural mesothelioma: current status and future directions 106
Superiority of CHOI vs RECIST criteria in evaluating outcome of advanced soft tissue sarcoma (STS) patients treated with sorafenib 105
Palonosetron plus 3-day aprepitant and dexamethasone to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy 105
Perfusion Computed Tomography as prognostic and predictive factor in patients with colorectal cancer liver metastases treated with bevacizumab 103
Survival outcome and prognostic factors after pulmonary metastasectomy in sarcoma patients 102
A monocentric retrospective analysis of TILs and AR as hints for prognosis definition in TNBC 102
Zoledronic acid (ZA) and treatment of bone metastasis in patients with advanced lung cancer (NSCLC and SCLC). 101
Safety and efficacy of oral combination of vinorelbine and capecitabine in metastatic breast cancer 101
Safety and efficacy of oral vinorelbine and capecitabine combination for metastatic breast cancer 100
Imatinib mesylate in desmoplastic small round cell tumour 98
Neutrophil to Lymphocyte Ratio (NLR) as predictive factor in patients with metastatic soft tissue sarcoma (STS) treated with trabectedin (T). 96
PERFUSION COMPUTED TOMOGRAPHY AS PROGNOSTIC AND PREDICTIVE FACTOR IN PATIENTS WITH COLORECTAL CANCER LIVER METASTASES TREATED WITH BEVACIZUMAB 93
Colorectal cancer liver metastases treated with target therapies: monitoring response with constrat-enhanced ultrasonography (CE-US). 90
Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 90
Carcinoma gastrico metastatico e Docetaxel, Cisplatino, Fluorouracile (DCF) settimanale: tolleranza e risposta 89
48P The relationship among bowel FDG-PET uptake, pathological complete response, and the influence of eating and exercise habits in breast cancer patients undergoing neoadjuvant chemotherapy 88
Atypical Lipomatous Tumors: Should They be Treated Like Other Sarcoma or Not? Surgical Consideration from a Bi-Institutional Experience 88
Phase II study: Docetaxel-cisplatin and pro drug tegafur (TPF) as neoadjuvant treatment in advanced patients with head and neck cancer (HNC): Results and correlation between tandem magnesium/creatinine and toxicity 87
Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. 87
Colorectal cancer liver metastases treated with target therapies: monitoring response with contrast-enhanced ultrasonography (CE-US). 82
Activity of regorafenib in advanced pretreated soft tissue sarcoma: Results of a single-center phase II study 82
Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapy 81
Clinical predictors of cardiac toxicity in HER2-positive early breast cancer patients treated with adjuvant s.c. versus i.v. trastuzumab 81
Response to Sunitinib in an Adult Patient With Rhabdoid Renal Cell Carcinoma 80
Early response evaluation of antiangiogenic therapy: use of contrast-enhanced ultrasonography (CE-US) in hepatocellular carcinoma 80
First-line chemotherapy in over-70 patients with colon cancer. 79
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer 78
Docetaxel in combination with gemcitabine as second line treatment in patients with platinum resistant advanced NSCLC 78
wALT trial (Phase I-II): weekly non-pegylated liposomal anthracycline and taxane combination in first line breast cancer chemotherapy 78
A pilot analysis of headache disorders in breast cancer patients 78
A Study of Clinical Features and Risk Factors of Self-Referring Emergency Department Headache Patients: A Comparison with Headache Center Outpatients 77
Capecitabine in elderly patients with metastatic breast cancer 77
WALT TRIAL (PHASE III): WEEKLY NON PEGYLATED LIPOSOMAL ANTHRACYCLINE AND TAXANE COMBINATION IN FIRSTLINE BREAST CANCER CHEMOTHERAPY 77
Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma 77
PET/CT radiomics in breast cancer: promising tool for prediction of pathological response to neoadjuvant chemotherapy 75
Safety and efficacy of bevacizumab with first-line FOLFIRI for metastatic colorectal cancer: single center experience 74
Dietary chemoprevention of colorectal cancer 74
Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial 74
Predictive Factors of Eribulin Activity in Metastatic Breast Cancer Patients 73
Efficacy and tolerability of a single-day three drugs combination of aprepitant, palonosetron and dexamethasone in patients receiving moderately emetogenic chemotherapy 73
Clinical Review on the Management of Breast Cancer Visceral Crisis 72
Capecitabine in elderly breast cancer patients 72
Phase I, pharmacokinetics, pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors 70
Long-term Follow-up and Post-relapse Outcome of Patients with Localized Retroperitoneal Sarcoma Treated in the Italian Sarcoma Group-Soft Tissue Sarcoma (ISG-STS) Protocol 0303 69
Descripcion de un sistema de realidad virtual dirigido a la promocion de bienestar emocional en pazientes oncologicoa hospidalizados: ensayo fase II OncoHelp 69
Unsupervised versus Supervised Identification of Prognostic Factors in Patients with Localized Retroperitoneal Sarcoma: A Data Clustering and Mahalanobis Distance Approach 67
Prognostic factors and outcome of HER2+ breast cancer with CNS metastases 67
Bevacizumab in combination with FOLFIRI as first-line treatment for metastatic colorectal cancer: outcomes from a single center experience 67
High-risk soft tissue sarcomas treated with perioperative chemotherapy: Improving prognostic classification in a randomised clinical trial 67
A Propensity Score Matching Study on the Effect of OnabotulinumtoxinA Alone versus Short-Term Psychodynamic Psychotherapy Plus Drug-of-Choice as Preventive Therapy in Chronic Migraine: Effects and Predictive Factors 66
Never too old to fight breast cancer 66
SAFETY AND EFFICACY OF SORAFENIB FOR ADVANCED HEPATOCELLULAR CARCINOMA 66
Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): long-term follow-up of a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group 66
HER2-positive breast cancer and CNS metastases: Prognostic factors and clinical outcome 65
Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase I-II study from the Italian Sarcoma Group 65
A systematic review of systematic reviews and pooled meta-analysis on pharmacological interventions to improve cancer-related fatigue 65
Non-pegylated liposomal doxorubicin plus ifosfamide in metastatic soft tissue sarcoma: results from a phase-II trial 63
Juxtaglomerular cell tumor: Multicentric synchronous disease associated with paraneoplastic syndrome 62
From seaside to bedside: Current evidence and future perspectives in the treatment of breast cancer using marine compounds 61
Opportunities and Challenges of Synthetic Data Generation in Oncology 61
Trabectedin for the treatment of soft tissues sarcomas 61
Platinum salts in the treatment of BRCA-associated breast cancer: A true targeted chemotherapy? 61
TNBC universe: A monocentric retrospective analyses of TILs and AR as prognostic markers 61
Primary breast leiomyosarcoma and synchronous homolateral lung cancer: a case report 61
Role of Surgery in the Multimodal Treatment of Primary and Recurrent Leiomyosarcoma of the Inferior Vena Cava 61
Efficacy of trabectedin in advanced soft tissue sarcoma: Beyond lipo- and leiomyosarcoma 61
Feasibility of preoperative chemotherapy with or without radiation therapy in localized soft tissue sarcomas of limbs and superficial trunk in the Italian sarcoma group/grupo español de investigación en sarcomas randomized clinical trial: Three versus five cycles of full-dose epirubicin plus ifosfamide 61
SAFETY AND EFFICACY OF ORAL COMBINATION CHEMOTHERAPY IN METASTATIC BREAST CANCER: VINORELBINE AND CAPECITABINE 59
The therapeutic potential of duloxetine in prostate cancer-related fatigue 59
Safety, tolerability and early response evaluation of sarafenib in hepatocellular carcinoma in erderly: use of contrast-enhanced ultrasonography (CE-US). 59
Trabectedin for the treatment of soft tissue sarcoma 58
Phase I, pharmacokinetic (PK), pharmacodynamic (PD) study of lapatinib (L) in combination with sorafenib (S) in patients with advanced refractory solid tumors 58
Common Misconceptions about Diet and Breast Cancer: An Unclear Issue to Dispel 57
Pulmonary sarcomatoid carcinoma presenting both ALK rearrangement and PD-L1 high positivity: A case report on the therapeutic regimen 57
Temporal–occipital glioblastoma presenting with Alice in Wonderland Syndrome in a patient with a long-time history of migraine without aura 57
Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets 56
Never too old to fight breast cancer: A case report 56
Primary ovarian insufficiency associated with pazopanib therapy in a breast angiosarcoma patient: A CARE-compliant case report 56
The Role of Female Reproductive Hormones in the Association between Migraine and Breast Cancer: An Unanswered Question 55
The role of docetaxel in the multimodal treatment of non-small cell lung cancer 55
Imatinib mesylate in desmoplastic small round cell tumors 54
Insights for the application of TILs and AR in the treatment of TNBC in routine clinical practice 54
Fulvestrant and trastuzumab in patients with luminal HER2-positive advanced breast cancer (ABC): an Italian real-world experience (HERMIONE 9) 54
Imaging Correlates between Headache and Breast Cancer: An [18F]FDG PET Study 54
Palonosetron plus three-day aprepitant and dexamethasone schedule to prevent nausea and vomiting in patients receiving highly emetogenic chemotherapy 53
Commentary: Improvement in diagnostic-therapeutic care pathways for women with migraine: an Italian Delphi panel 53
[Integrated treatment of breast cancer: review of our experience] 52
Profiling the Spectrum of Headache Disorders on 440 Breast Cancer Patients: Highlights on Clinical and Pathological Mechanisms 51
[The clinical significance of lymph node micrometastases and of concept of sentinel lymph node] 51
Phase I, Pharmacokinetics (PK), Pharmacodynamic (PD) Study of Lapatinib (L) in Combination With Sorafenib (S) in Patients With Advanced Refractory Solid Tumours 51
Sporadic desmoid tumors of the abdominal wall: the results of surgery 51
Charting the Course in Sequencing Antibody-Drug Conjugates in Breast Cancer 50
Unveiling the HER2-low phenomenon: exploring immunohistochemistry and gene expression to characterise HR-positive HER2-negative early breast cancer 48
Nomograms predicting local and distant recurrence and disease-specific mortality for R0/R1 soft tissue sarcomas of the extremities 48
Potential Role of Circulating miRNAs for Breast Cancer Management in the Neoadjuvant Setting: A Road to Pave 48
Defining T cell dysfunctionality in breast cancer by single cell analysis: Implications for immunotherapy 47
Sticking to the Rules: Outcome and Success Rate of Guideline-Based Diarrhea Management in Metastatic Breast Cancer Patients Treated with Abemaciclib 46
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 46
Totale 7.102
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.182
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 54.182
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202197 0 0 0 0 0 0 0 0 0 0 0 97
2021/2022445 32 2 15 79 14 7 12 64 44 77 89 10
2022/2023898 182 19 114 58 79 46 4 72 137 97 78 12
2023/2024779 54 63 164 34 30 110 52 32 8 21 67 144
2024/20251.215 27 3 4 11 15 173 51 118 216 276 151 170
2025/20263.696 486 621 236 419 154 150 825 170 216 212 105 102
Totale 8.064